List of not more than ten outpatient prescription drugs pursuant to Conn. Gen. Stat. §19a-754b(d)

Statutory Reference: Conn. Gen. Stat. §19a-754b

OHS developed the list based on the specifications outlined in Conn. Gen. Stat. § 19a-754b(b)(1), specifically:

- The list must include at least one generic drug;
- The list must include drugs from different therapeutic classes;
- *The list cannot include any drugs that did not have at least a 20% increase in cost during the past year or 50% during the past three years; and
- *The list cannot include any drugs that were less than $60 for either a 30-day supply or a course of treatment lasting less than 30 days.

*The statute required that these two criteria to be based upon the wholesale acquisition cost of the drug, less all rebates paid to the state for the drug, which is unavailable data.

Methodology: The Office of Health Strategy utilized the statutory criteria of $60 for a thirty-day supply or course of treatment for less than thirty-days to identify the top 50 outpatient prescription drug by NDCs and then provided the list to OSC for State of CT employee and retiree utilization. Cost for an NDC is the allowed amount for a pharmacy claim i.e., the sum of state paid amount and member out of pocket cost (deductible, co-insurance and co-pay). The OSC and CVS then identified NDCs with the highest State of CT expenditures and then appended the wholesale acquisition cost (WAC).

Finding: OHS reviewed the increases over the last year and four years and determined that none of the drugs by NDC met the statutory criteria of 20% increase from 2019 - 2020, or 50% increase from 2017 - 2020.

Source of Data: The Office of Health Strategy (OHS) reviewed the 2021 drug list using the Office of the State Comptroller’s Connecticut Employee/Retiree Health Plan claims data for State Fiscal Year (SFY) 2017 through 2020. The data was obtained from the State Plan administrator, CVS/Caremark.

OHS plans to release separate information or data that provides useful information to enhance transparency. The additional lists will also be based on the state plan dataset.

This listing and any additional list or data releases which OHS posts or makes available, will not trigger the information and data filings required by Conn. Gen. Stat. § 19a-754b (c)(2) from drug manufacturers, until the next list is released in March 2022.